Maturitas
Volume 54, Issue 2 , Pages 154-163 , 20 May 2006

Which progestogen is more likely to increase the risk of fatal myocardial infarction: A combination of epidemiological and trial evidence

  • Farook Al-Azzawi

      Affiliations

    • Gynaecology Research Unit, University Hospitals of Leicester, Leicester LEI 5WW, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 116 258 7506; fax: +44 116 258 6089.
    • ,
  • John Thompson

      Affiliations

    • Department of Epidemiology, Leicester and Warwick Medical School, University of Leicester, Leicester, UK
    • ,
  • John Stevenson

      Affiliations

    • Imperial College, London, UK

Received 9 February 2005 ,Revised 21 September 2005 ,Accepted 7 October 2005.

References 

  1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  2. McNagny SE, Wenger NK, Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med. 1997;127:1093–1096
  3. Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas. 1997;28:137–145
  4. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534
  5. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89:157–161
  6. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98:83–90
  7. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J. 1988;115:954–963
  8. Lobo RA. Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925–930
  9. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196–1204
  10. Farish E, Fletcher CD, Hart DM, Dagen MM, Parkin DE. Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta. 1986;159:147–151
  11. Gordon DJ, Rifkind BM. High-density lipoprotein—the clinical implications of recent studies. N Engl J Med. 1989;321:1311–1316
  12. Marsh MS, Crook D, Whitcroft SI, Worthington M, Whitehead MI, Stevenson JC. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol. 1994;83:19–23
  13. LaRosa JC. Metabolic effects of estrogens and progestins. Fertil Steril. 1994;62:140S–146S
  14. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb. 1994;14:275–281
  15. Chen FP, Lee N, Soong YK. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone. J Reprod Med. 1998;43:568–574
  16. Tremollieres FA, Pouilles JM, Ribot CA. A prospective 2-year study of progestin given alone in postmenopausal women: effect on lipid and metabolic parameters. Am J Obstet Gynecol. 1995;173:85–89
  17. Steinberg D. The cholesterol controversy is over. Why did it take so long?. Circulation. 1989;80:1070–1078
  18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  19. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009
  20. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  21. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998;19:1434–1503
  22. Krauss RM, Perlman JA, Ray R, Petitti D. Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am J Obstetr Gynecol. 1988;158:1606–1611
  23. Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994;35:779–792
  24. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988–1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem. 1997;43:2364–2378
  25. Connelly PW, Poapst M, Davignon J, et al. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group. Can J Cardiol. 1999;15:409–418
  26. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481–488
  27. Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–2756
  28. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–541
  29. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495–1508
  30. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000;41:1481–1494
  31. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from d-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290–292
  32. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoproteinmediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:3215–3220
  33. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management?. Arteriosclerosis. 1990;10:668–671
  34. Sniderman AD, Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias. Clin Chem. 1996;42:489–491
  35. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343:75–79
  36. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273–278
  37. Rosseneu M, Fruchart JC, Bard JM, et al. Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. European Atherosclerosis Research Study. Circulation. 1994;89:1967–1973
  38. Sniderman AD. Counterpoint: to (measure apo) B or not to (measure apo) B: a critique of modern medical decision-making. Clin Chem. 1997;43:1310–1314
  39. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777–780
  40. Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem. 1991;37:1676–1682
  41. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem. 1992;38:658–662
  42. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem. 1993;39:773–781
  43. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 1994;40:586–592
  44. Labeur C, Shepherd J, Rosseneu M. Immunological assays of apolipoproteins in plasma: methods and instrumentation. Clin Chem. 1990;36:591–597
  45. Stein E. Clinical significance and measurement of apolipoproteins A-1 and B. In:  Rifai N,  Warnick G editor. Laboratory measurement of lipids, lipoproteins and apolipoproteins. Washington, DC: AACC Press; 1994;p. 141–154
  46. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–2033
  47. Schaefer EJ, McNamara JR. Routine diagnostic testing for apoA-I, apo-B, Lp(a), and LDL cholesterol in clinical laboratories. Clin Lab Sci. 1994;7:205–208
  48. Garfagnini A, Devoto G, Rosselli P, Boggiano P, Venturini M. Relationship between HDL-cholesterol and apolipoprotein A1 and the severity of coronary artery disease. Eur Heart J. 1995;16:465–470
  49. Westerveld HT, van Lennep JE, van Lennep HW, et al. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol. 1998;18:1101–1107
  50. Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk-apolipoprotein AI as an independent risk factor. Atherosclerosis. 2001;155:165–170
  51. Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnance progestin (trimegestone). Gynecol Endocrinol. 1999;13:316–326
  52. Al-Azzawi F, Wahab M, Sami S, Proudler AJ, Thompson J, Stevenson JC. Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women. Climacteric. 2004;7:292–300
  53. Al-Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric. 2001;4:343–354
  54. Schafer JL. Analysis of incomplete multivariate data. London: Chapman and Hall; 1997;
  55. Graziani MS, Zanolla L, Righetti G, Marchetti C, Mocarelli P, Marcovina SM. Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group. Clin Chem. 1998;44:134–140
  56. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886–1892
  57. van Lennep JE, Westerveld HT, van Lennep HW, Zwinderman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000;20:2408–2413
  58. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem. 1991;266:3080–3086
  59. Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 1999;354:1341–1346
  60. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352–355
  61. Arakawa R, Abe-Dohmae S, Asai M, Ito JI, Yokoyama S. Involvement of caveolin-1 in cholesterol enrichment of high density lipoprotein during its assembly by apolipoprotein and THP-1 cells. J Lipid Res. 2000;41:1952–1962
  62. Fielding CJ, Bist A, Fielding PE. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci USA. 1997;94:3753–3758
  63. Kojima K, Abe-Dohmae S, Arakawa R, Murakami I, Suzumori K, Yokoyama S. Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta. 2001;1532:173–184
  64. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712

PII: S0378-5122(05)00263-X

doi: 10.1016/j.maturitas.2005.10.004

Maturitas
Volume 54, Issue 2 , Pages 154-163 , 20 May 2006

Article Tools

* Image Usage & Resolution